Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Get Rating) – Research analysts at Cantor Fitzgerald issued their FY2023 earnings per share (EPS) estimates for shares of Rani Therapeutics in a research report issued on Monday, June 6th. Cantor Fitzgerald analyst B. Folkes forecasts that the company will earn ($1.40) per share for the year.
Rani Therapeutics (NASDAQ:RANI – Get Rating) last posted its earnings results on Wednesday, May 11th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.71.
Separately, Zacks Investment Research upgraded shares of Rani Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research report on Thursday, June 2nd. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $21.40.
RANI opened at $9.32 on Thursday. The firm has a 50-day moving average price of $11.91 and a 200-day moving average price of $16.06. Rani Therapeutics has a twelve month low of $9.10 and a twelve month high of $36.27.
A number of institutional investors have recently made changes to their positions in the business. United Services Automobile Association bought a new stake in Rani Therapeutics during the first quarter valued at approximately $6,498,000. Vanguard Group Inc. lifted its position in Rani Therapeutics by 1.6% during the first quarter. Vanguard Group Inc. now owns 290,107 shares of the company’s stock valued at $3,916,000 after purchasing an additional 4,561 shares during the last quarter. BlackRock Inc. lifted its position in Rani Therapeutics by 37.7% during the first quarter. BlackRock Inc. now owns 157,374 shares of the company’s stock valued at $2,125,000 after purchasing an additional 43,076 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Rani Therapeutics by 192.1% in the 4th quarter. Geode Capital Management LLC now owns 63,217 shares of the company’s stock worth $1,033,000 after acquiring an additional 41,578 shares during the last quarter. Finally, Lasry Marc bought a new stake in shares of Rani Therapeutics in the 1st quarter worth approximately $848,000. Institutional investors and hedge funds own 2.31% of the company’s stock.
Rani Therapeutics Company Profile (Get Rating)
Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes.
Receive News & Ratings for Rani Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Rani Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.